Researchers and clinicians are working miracles in medicine these days because of breakthroughs in therapies that have received crucial backing from the alternative investment industry.
There is much more work to be done, and that’s what drives the staff of RTW Investments. “This is the start of an amazing next generation of innovation,” said Stephanie Sirota, chief business officer at RTW. “You have a wonderful advantage when you start evaluating the science, before it is even investible.”
These innovations have included the rapid development of safe and effective RNA vaccines against COVID 19 and . . .
Unlock this article instantly, along with the rest of our premium content, newsletters and data tables tracking investor and manager activity. Annual subscriptions get you the most bang for your buck, including access to Alternatives Watch Research articles and out Annual Investor Compendium.
Monthly subscriptions and discounted corporate plans for up to 100 members also available.